Recro Pharma, Inc. REPH Income Statement

Recro pharma, inc. (REPH)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Revenue
95,931	99,219	99,359	92,387	82,870	77,347	76,678	75,329	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Manufacturing, royalty and profit sharing revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	-	-	-	-	-	-	-	-	-
Research and development revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	-	-	-	-	-	-	-	-	-
Revenue
-	-	-	-	-	-	-	-	-	-	-	-	70,337	-	68,511	70,220	0	-	0	0	-	-	-	-	-	-	-	-	-
Operating expenses:
Cost of sales (excluding amortization of intangible assets)
54,844	50,981	51,645	49,090	47,061	43,160	41,398	39,808	38,185	38,193	39,417	38,280	37,379	37,152	35,602	39,252	0	-	0	0	-	-	-	-	-	-	-	-	-
Research and development
-	-	-6,966	2,537	-	4,402	10,275	8,223	5,139	4,460	34,236	31,986	33,233	33,278	28,163	23,833	18,334	12,281	9,467	10,385	9,401	7,874	5,759	2,248	656	543	0	0	0
Selling, general and administrative
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
-	-	38,492	38,582	-	-	37,879	37,545	30,912	-	20,469	17,675	14,116	12,742	13,818	13,455	13,289	13,017	9,768	7,374	5,736	3,997	2,779	1,856	1,101	546	0	0	0
Amortization of intangible assets
2,583	2,583	2,583	2,583	2,583	2,583	2,583	2,583	2,583	2,583	2,583	2,583	2,583	2,583	2,584	2,530	0	-	0	0	-	-	-	-	-	-	-	-	-
Change in warrant valuation
-	2,116	1,301	1,428	-752	284	-85	436	491	9	-406	-812	1,512	-373	-714	-234	0	-	0	0	-	-	-	-	-	-	-	-	-
Change in contingent consideration valuation
-	-	-13,774	-13,568	-	-	10,547	9,982	12,545	-	11,347	10,989	9,564	9,728	8,290	7,098	0	-	0	0	-	-	-	-	-	-	-	-	-
Total operating expenses
78,656	75,589	40,204	47,575	53,756	64,866	78,656	74,636	65,914	59,569	107,646	100,701	98,387	95,110	84,392	81,807	0	-	0	0	-	-	-	-	-	-	-	-	-
Operating income from continuing operations
-	-	49,218	37,897	-	12,481	-2,815	935	5,837	12,265	-42,119	-35,604	-33,164	-31,312	-22,121	-18,071	0	-	0	0	-	-	-	-	-	-	-	-	-
Operating income (loss) from continuing operations
0	-	-9,505	-23,848	0	-	-52,624	-49,773	-45,856	-	-37,491	-30,709	-28,050	-25,773	-15,881	-11,587	0	-	0	0	-	-	-	-	-	-	-	-	-
Total operating expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15,138	11,871	8,539	4,104	1,757	1,089	0	0	0
Other income (expense):
Interest income
656	801	941	744	676	643	467	403	406	369	306	254	145	49	29	21	17	12	13	15	14	10	7	2	0	0	0	0	0
Grant income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Interest expense
21,194	19,806	16,818	13,599	10,418	8,756	14,899	13,936	12,954	12,034	4,934	5,149	5,259	5,588	6,269	6,507	0	-	0	0	-	4,272	4,504	4,725	4,937	868	0	0	0
Income tax expense
-	-	-	-	-	17,436	4,666	4,215	5,257	7,317	-5,720	-2,881	-1,411	-1,107	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) from continuing operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on discontinued operations
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14	-4,262	-4,497	-4,722	-4,937	-868	0	0	0
Net loss
-24,345	-18,630	-50,416	-59,367	-69,245	-79,723	-62,511	-58,310	-54,450	-50,082	-36,399	-32,723	-31,753	-30,205	0	0	0	-	-	-	-15,124	-16,134	-13,037	-8,827	-6,695	-1,957	0	0	0
Per share information:
Net income (loss) per share from continuing operations, basic
-0.33	-	-	-	0.01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share from discontinued operations, basic
-	-	-	-	-0.10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of redeemable convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,270	1,383	1,493	1,605	440	0	0	0
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11,080	-13,641	-15,124	-17,404	-14,420	-10,320	-8,301	-2,398	0	0	0
Net loss per share of common stock, basic and diluted
-	-	-0.19	-0.13	-	-	-0.64	-0.62	-	-	-0.48	-	-0.42	-	-0.50	-	-0.71	-	-0.24	-0.17	-0.53	1.85	-0.61	-0.36	-3.67	-3.19	-3.95	-4.97	-3.30
Weighted average common shares outstanding, basic and diluted
-	-	22,505	22,265	-	-	20,721	20,410	-	-	19,058	-	19,049	-	10,780	-	9,251	-	9,118	7,829	7,768	7,789	7,707	7,707	1,749	155	155	155	155
Net loss per share, basic
-0.33	-	-	-	-0.09	-	-	-	-0.65	-	-	-0.46	-	-	-	-0.83	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average common shares outstanding, basic
23,394	-	-	-	21,918	-	-	-	19,219	-	-	19,052	-	-	-	9,544	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) per share from continuing operations, diluted
-0.33	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share from discontinued operations, diluted
-	-	-	-	-0.10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share, diluted
-0.33	-	-	-	-0.10	-	-	-	-0.65	-	-	-0.48	-	-	-	-0.83	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average common shares outstanding, diluted
23,394	-	-	-	21,978	-	-	-	19,219	-	-	19,220	-	-	-	9,544	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-24,345	-18,630	-50,416	-59,367	-69,245	-79,723	-62,511	-58,310	-54,450	-50,082	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other comprehensive loss:
Unrealized gain/(loss) on available-for-sale securities
-	-	0	0	0	-	-	0	-	-1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-24,344	-18,630	-50,416	-59,367	-69,245	-79,722	-62,503	-58,234	-54,394	-50,083	-36,407	-32,799	-31,810	-30,205	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-